Latest
-
Why you should keep the faith in Kier Group
Features Engineering firm Kier Group has hit trouble, but the core business looks sound, says Matthew Partridge.
Features -
After the Woodford fallout, is it time to buy Hargreaves Lansdown and Patient Capital?
Features Two of the biggest casualties from Neil Woodford’s fall from grace are his investment trust - Woodford Patient Capital - and broker Hargreaves Lansdown. John Stepek looks at whether you should snap them up or leave them well alone.
Features -
Is Kier Group worth buying after its post-profit-warning share-price plunge?
Features Shares at construction and outsourcing contractor Kier Group have taken a nosedive. Matthew Partridge examines why and asks if now is a good time to buy.
Features
